Home・Elenco Azioni・Bio-Techne Corp

Bio-Techne Corp

Aperta

SettoreSettore sanitario

72.59 0.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.54

Massimo

72.63

Metriche Chiave
By Trading Economics
Entrata	3.6M 55M
Vendite	9.8M 321M
P/E Media del settore	62.474 55.725
EPS	0.49
Rendimento da dividendi	0.44
Margine di Profitto	17.006
Dipendenti	3,000
EBITDA	-6.7M 92M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+0.59% upside

Dividendi
By Acuity
Rendimento da dividendi Media del settore	0.44% 2.25%
Utili prossimi	4 nov 2026
Prossima data del Dividendo	27 nov 2026
Prossima data del' Ex Dividendo	16 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	128M 11B
Apertura precedente	72.53
Chiusura precedente	72.59

Notizie sul Sentiment di mercato

By Acuity

50%

118 / 339 Classifica in Healthcare

Bio-Techne Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2026, 19:47 UTC

Correlated Moves

Bio-Techne Corp shares are lower today, reflecting a decline since Friday. Agilent Technologies' drop may be influencing Bio-Techne's performance amid inflation data focus.

28 ago 2026, 19:46 UTC

Correlated Moves

Bio-Techne Corp is trading lower today, reflecting a broader decline in the biotech sector, including Charles River Laboratories International Inc.

27 ago 2026, 23:31 UTC

Bio-Techne Corp shares are higher in after-market hours, though no specific news was identified. Recent economic data showed a decline in initial jobless claims.

19 ago 2026, 19:27 UTC

Correlated Moves

Shares modestly higher, influenced by rise in iShares Biotechnology ETF.

18 ago 2026, 21:41 UTC

Bio-Techne Corp shares are higher in after-market trading, peaking early in the session and remaining near the upper end of their one-month trading range.

17 ago 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat amid broader market sentiment, with the Russell 2000 Index declining. Recent economic data has contributed to cautious conditions.

13 ago 2026, 19:16 UTC

Correlated Moves

News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5 ago 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4 ago 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3 ago 2026, 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31 lug 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30 lug 2026, 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29 lug 2026, 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20 lug 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Confronto tra pari

Modifica del prezzo

Bio-Techne Corp Previsione

Obiettivo di Prezzo

By TipRanks

0.59% in crescita

Previsioni per 12 mesi

Media 73 USD 0.59%

Alto 73 USD

Basso 73 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bio-Techne Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Bio-Techne Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

118 / 339 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.